penetrate into the modified release portion,
[12] the pharmaceutical composition for oral administration of [11], wherein the additive which allows water to penetrate into the modified release portion has a solubility such that the amount of water necessary to dissolve 1 g of the additive is 10 mL or less,
[13] the pharmaceutical composition for oral administration of [11] or [12], wherein the content of the additive which allows water to penetrate into the modified release portion is about 5% by weight to about 75% by weight with respect to the weight of the modified release portion,
[14] the pharmaceutical composition for oral administration of any one of [1] to [13], which is a pharmaceutical composition for treating urinary urgency, urinary frequency, and/or urge urinary incontinence associated with overactive bladder,
[15] the pharmaceutical composition for oral administration of any one of [1] to [14], wherein the pharmaceutical composition is a tablet,
[16] the pharmaceutical composition for oral administration of [15], which is a bi-layered tablet, and
[17] a pharmaceutical composition for oral administration comprising (1) a layer comprising mirabegron or a pharmaceutically acceptable salt thereof, and (2) a layer comprising solifenacin or a pharmaceutically acceptable salt thereof, and calcium stearate.

[18] Use of the pharmaceutical composition as disclosed herein, in the manufacture of a medicament for treating urinary urgency, urinary frequency, and/or urge urinary incontinence associated with overactive bladder.

ADVANTAGEOUS EFFECTS OF INVENTION
[0018]

The present invention provides a pharmaceutical composition for oral administration comprising a modified release portion containing mirabegron or a pharmaceutically acceptable salt thereof, and an immediate release portion containing solifenacin or a pharmaceutically acceptable salt thereof. The pharmaceutical composition for oral administration of the present invention has a drug release similar to that of each current formulation (single drug formulation), and thus, a single formulation (combined formulation) capable of expecting pharmacological effects

8. The pharmaceutical composition for oral administration according to claim 7, wherein the hydrogel-forming polymer is one polymer or two or more polymers selected from the group consisting of polyethylene oxide, hypromellose, hydroxypropylcellulose, methylcellulose, carboxymethylcellulose sodium, hydroxyethylcellulose, and a carboxyvinyl polymer.

9. The pharmaceutical composition for oral administration according to claim 8, wherein the hydrogel-forming polymer is polyethylene oxide.

10. The pharmaceutical composition for oral administration according to any one of claims 6 to 9, wherein the content of the hydrogel-forming polymer is about 1% by weight to about 70% by weight with respect to the weight of the modified release portion.

11. The pharmaceutical composition for oral administration according to any one of claims 1 to 10, wherein the modified release portion further contains an additive which allows water to penetrate into the modified release portion.

12. The pharmaceutical composition for oral administration according to claim 11, wherein the additive which allows water to penetrate into the modified release portion has a solubility such that the amount of water necessary to dissolve 1 g of the additive is 10 mL or less.

13. The pharmaceutical composition for oral administration according to claim 11 or 12, wherein the content of the additive which allows water to penetrate into the modified release portion is about 5% by weight to about 75% by weight with respect to the weight of the modified release portion.

~~14. The pharmaceutical composition for oral administration according to any one of claims 1 to 13, which is a pharmaceutical composition for treating urinary urgency, urinary frequency, and/or urge urinary incontinence~~

~~associated with overactive bladder.~~

~~15~~14. The pharmaceutical composition for oral administration according to any one of claims 1 to ~~14~~13, wherein the pharmaceutical composition is a tablet.

~~16~~15. The pharmaceutical composition for oral administration according to claim ~~15~~14, which is a bi-layered tablet.

16. Use of the pharmaceutical composition according to any one of claims 1 to 15, in the manufacture of a medicament for treating urinary urgency, urinary frequency, and/or urge urinary incontinence associated with overactive bladder.

~~17~~18. A pharmaceutical composition for oral administration comprising:

(1) a layer comprising mirabegron or a pharmaceutically acceptable salt thereof, and

(2) a layer comprising solifenacin or a pharmaceutically acceptable salt thereof, and calcium stearate.